Comparative Pharmacology
Head-to-head clinical analysis: KADCYLA versus TIBSOVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KADCYLA versus TIBSOVO.
KADCYLA vs TIBSOVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
500 mg orally once daily taken with or without food.
None Documented
None Documented
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Terminal elimination half-life: 50-60 hours, supporting once-daily dosing with steady-state reached in approximately 2 weeks.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Primarily hepatic metabolism (CYP3A4) and fecal excretion (77% unchanged and metabolites); renal elimination accounts for <1% of absorbed dose.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent